Kinetic modelling of NSAID action on COX-1: Focus on in vitro/in vivo aspects and drug combinations

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 122-136

  Goltsov, Alexey ^a   Maryashkin, Anton ^b   Swat, Maciej ^c   Kosinsky, Yuri ^b,d   Humphery Smith, Ian ^e   Demin, Oleg ^c,d   Goryanin, Igor ^a   Lebedeva, Galina ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Institute for Systems Biology SPb   (Russian Federation)

^c CERTARA UK LIMITED   (United Kingdom)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e Deomed   (United Kingdom)

Author keywords

Aspirin; Celecoxib; Cyclooxygenase; Drug combination; Kinetic model; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ETORICOXIB; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PROSTAGLANDIN SYNTHASE; THROMBOXANE; VALDECOXIB;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CATALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; THROMBOCYTE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATALYSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; KINETICS; MODELS, STATISTICAL; PYRAZOLES; SULFONAMIDES;

EID: 58149136055     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.015     Document Type: Article

References (29)

1. Bambai B., Rogge C.E., Stec B., and Kulmacz R.J. Role of Asn-382 and Thr-383 in activation and inactivation of human prostaglandin H synthase cyclooxygenase catalysis. J. Biol. Chem. 279 (2004) 4084-4092
2. Brash A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 107 (2001) 1339-1345
3. Brooks P., Emery P., Evans J.F., Fenner H., Hawkey C.J., Patrono C., Smolen J., Breedveld F., Day R., Dougados M., Ehrich E.W., Gijon-Baños J., Kvien T.K., Van Rijswijk M.H., Warner T., and Zeidler H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 38 (1999) 779-788
4. Burch J.W., Baenziger N.L., Stanford N., and Majerus P.W. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 5181-5184
5. Callan O.H., So O.-Y., and Swinney D.C. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem. 271 (1996) 3548-3554
6. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., Di Gregorio P., Merciaro G., and Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 45 (2005) 1295-1301
7. Chan C.-C., Boyce S., Brideau C., Charleson C., Cromlish W., Ethier D., Evans J., Ford-Hutchinson S.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., Rodger I., et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharm. Exp. Ther. 290 (1999) 551-560
8. Chen W., Pawelek T.R., and Kulmacz R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 274 (1999) 20301-20306
9. Curtis J.P., and Krumholz H.M. The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: is it time to believe the hype?. J. Am. Coll. Cardiol. 43 (2004) 991-993
10. Gierse J.K., Koboldt C.M., Walker M.C., Seibert K., and Isakson P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339 (1999) 607-614
11. Goryanin I., Hodgman T.C., and Selkov E. DBsolve: mathematical simulation and analysis of cellular metabolism and regulation. Bioinformatics 15 (1999) 749-758
12. Grosser T., Fries A., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
13. Howard P.A., and Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J. Am. Coll. Cardiol. 43 (2004) 519-525
14. Kargman A., Wong E., Greig G.M., Falgueyret J.P., Cromlish W., Ethier D., Yergey J.A., Riendeau D., Evans J.F., Kennedy B., Tagari P., Francis D.A., and O'Neill G.P. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol. 52 (1996) 1113-1125
15. Karthein R., Dietz R., Nastainczyk W., and Ruf H.H. Higher oxidation states of prostaglandin H synthase. EPR study of a transient tyrosyl radical in the enzyme during the peroxidase reaction. Eur. J. Biochem. 171 (1988) 313-320
16. Kulmacz R.J. Topography of prostaglandin H synthase. antiinflammatory agents and the protease-sensitive arginine 253 region. J. Biol. Chem. 264 (1989) 14136-14144
17. Kulmacz R.J., Pendleton R.B., and Lands W.E. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J. Biol. Chem. 269 (1994) 5527-5536
18. Kulmacz R.J., van der Donk W.A., and Tsai A.-L. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res. 42 (2003) 377-404
19. Lu G., Tsai A.L., Van Wart H.E., and Kulmacz R.J. Comparison of the peroxidase reaction kinetics of prostaglandin H synthase-1 and -2. J. Biol. Chem. 74 (1999) 16162-16177
20. Mbonye U.R., Wada M., Rieke C.J., Tang H.Y., Dewitt D.L., and Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J. Biol. Chem. 281 (2006) 35770-35778
21. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., and Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U.S.A. 90 (1994) 11693-11697
22. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., and Warner T.D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20 (2006) 2468-2475
23. Ouellet M., Riendeau D., and Percival M.D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 14583-14588
24. Renda G., Tacconelli A., Capone M.L., Sacchetta D., Santarelli F., Sciulli M.G., Zimarino M., Grana M., D'amelio E., Zurro M., Price T.A., Patrono C., De Caterina R., and Patrignani P. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin. Pharmacol. Ther. 80 (2006) 264-274
25. Rome L.H., and Lands W.E.M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A. 72 (1975) 4863-4865
26. Sergeeva M.G., and Varfolomeeva A.T. Cascade of Arachidonic Acid (2006), Public Education, Moscow [in Russian]
27. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7563-7568
28. Wei C., Kulmacz R.J., and Tsai A.L. Comparison of branched-chain and tightly coupled reaction mechanisms for prostaglandin H synthase. Biochemistry 34 (1995) 8499-8512
29. Wu G., Kulmacz R.J., and Tsai A.L. Cyclooxygenase inactivation kinetics during reaction of prostaglandin H synthase-1 with peroxide. Biochemistry 42 (2003) 13772-13777